This was a test case by Isis to explore the potential overlaps in their RNA targeting technologies...
This reection has no impact on their numerous existing patents...however succes in the patent re-examination would have thrown Santris into a spin with significant benefits to Isis.
The test has been rejected, confirming the validity of Santaris patents.
So...the status quo remains unchanged.
Further to this, ANP have their own patents, in addition to the Isis patents.
Their technology is well protected.
Thanks for the article.
Cheers!
ANP Price at posting:
29.0¢ Sentiment: Buy Disclosure: Held
